Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
PLoS One. 2012;7(3):e32999. doi: 10.1371/journal.pone.0032999. Epub 2012 Mar 7.
Micro-RNAs (miRNAs) have recently emerged as crucial modulators of molecular processes involved in chronic liver diseases. The few miRNAs with previously proposed roles in liver cirrhosis were identified in screening approaches on liver parenchyma, mostly in rodent models. Therefore, in the present study we performed a systematic screening approach in order to identify miRNAs with altered levels in the serum of patients with chronic liver disease and liver cirrhosis.
We performed a systematic, array-based miRNA expression analysis on serum samples from patients with liver cirrhosis. In functional experiments we evaluated the relationship between alterations of miRNA serum levels and their role in distinct cellular compartments involved in hepatic cirrhosis.
The array analysis and the subsequent confirmation by qPCR in a larger patient cohort identified significant alterations in serum levels of miR-513-3p, miR-571 and miR-652, three previously uncharacterized miRNAs, in patients with alcoholic or hepatitis C induced liver cirrhosis. Of these, miR-571 serum levels closely correlated with disease stages, thus revealing potential as a novel biomarker for hepatic cirrhosis. Further analysis revealed that up-regulation of miR-571 in serum reflected a concordant regulation in cirrhotic liver tissue. In isolated primary human liver cells, miR-571 was up-regulated in human hepatocytes and hepatic stellate cells in response to the pro-fibrogenic cytokine TGF-β. In contrast, alterations in serum levels of miR-652 were stage-independent, reflecting a concordant down-regulation of this miRNA in circulating monocytes of patients with liver cirrhosis, which was inducible by proinflammatory stimuli like bacterial lipopolysaccharide.
Alterations of miR571 and miR-652 serum levels in patients with chronic liver disease reflect their putative roles in the mediation of fibrogenic and inflammatory processes in distinct cellular compartments involved in the pathogenesis of liver cirrhosis.
微小 RNA(miRNAs)最近成为涉及慢性肝病的分子过程的关键调节剂。少数先前被提出在肝硬化中起作用的 miRNAs 是在肝实质的筛选方法中鉴定的,主要是在啮齿动物模型中。因此,在本研究中,我们进行了系统的筛选方法,以鉴定慢性肝病和肝硬化患者血清中水平改变的 miRNAs。
我们对肝硬化患者的血清样本进行了系统的基于阵列的 miRNA 表达分析。在功能实验中,我们评估了 miRNA 血清水平的变化与其在涉及肝硬变的不同细胞区室中的作用之间的关系。
阵列分析和随后在更大的患者队列中通过 qPCR 的确认确定了酒精性或丙型肝炎诱导的肝硬化患者血清中 miR-513-3p、miR-571 和 miR-652 三种以前未被描述的 miRNAs 水平的显著改变。在这些中,miR-571 血清水平与疾病阶段密切相关,因此显示出作为肝纤维化的新生物标志物的潜力。进一步的分析表明,血清中 miR-571 的上调反映了肝硬化组织中一致的调节。在分离的原代人肝细胞中,miR-571 在人肝细胞和肝星状细胞中被上调以响应促纤维化细胞因子 TGF-β。相比之下,miR-652 血清水平的改变与疾病阶段无关,反映了肝硬化患者循环单核细胞中该 miRNA 的一致下调,这可被促炎刺激物如细菌脂多糖诱导。
慢性肝病患者 miR571 和 miR-652 血清水平的改变反映了它们在调节纤维化和炎症过程中的潜在作用,这些过程涉及肝硬化发病机制中的不同细胞区室。